Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

About this update from Neurocrine Biosciences, Inc.

[{"type":"text","content":"SAN DIEGO, Oct. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA® (valbenazine) capsules in reducing abnormal movements in adults with tardive dyskinesia (TD), a potentially irreversible and often persistent involuntary movement disorder. The analyses of pooled data from multiple long-term studies of the 40 mg dose showed that 53.7% of patients taking 40 mg of INGREZZA achieved an Abnormal Involuntary Movement Scale (AIMS) response (≥ 50% improvement from baseline) after 48 weeks of treatment. INGREZZA is available in two doses, 40 mg and 80 mg. Additionally, an analysis of the pivotal Phase III KINECT 3 data demonstrated that 50% of patients achieved an early response after two weeks of INGREZZA treatment (40 mg or 80 mg). Data also showed that meaningful long-term reductions in TD were achieved regardless of whether patients responded after two weeks. These long-term INGREZZA data were presented today at the 2019 Annual Psych Congress in San Diego. \n\n \n\"Tardive dyskinesia is a persistent and often irreversible movement disorder, and it can look and feel different from one patient to another, with each patient having distinct treatment needs,\" said Craig Chepke, M.D., Adjunct Assistant Professor of Psychiatry, University of North Carolina School of Medicine. \"Long-term data from the pooled analyses are important as they show that the 40 mg dose of INGREZZA is effective in reducing the troublesome movements of tardive dyskinesia in over 50% of patients. Many patients feel embarrassed, endure social isolation and experience even greater stigma associated with their existing mental illness, so having two effective dosing options of INGREZZA gives healthcare providers a choice in what will work best to manage the burdensome and disruptive involuntary movements associated with tardive dyskinesia.\"\nINGREZZA is the first U.S. Food and Drug Administration (FDA) approved treatment for adults with TD, a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts. The abnormal and involuntary movements of TD can impact patients socially, emotionally and physically, causing patients to feel embarrassed or judged by others...

More updates from Neurocrine Biosciences, Inc.